Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310296 · ClinicalTrials.gov registry record · Phase 1
Lofexidine ADME & Mass Balance in Volunteers
A Phase 1 study, sponsored by USWM, LLC (dba US WorldMeds).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01310296 is a Phase 1 study that has completed, run by USWM, LLC (dba US WorldMeds). The registered enrollment target is 12 participants.
The verdict
NCT01310296, a Phase 1 study, has completed, sponsored by USWM, LLC (dba US WorldMeds).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the mass balance and absolute bioavailability of a single oral dose of 14C-labeled lofexidine compared to a single intravenous dose of lofexidine.
Interventions
- DRUG Lofexidine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310296
The ClinicalTrials.gov registry entry for NCT01310296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is USWM, LLC (dba US WorldMeds), which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lofexidine hydrochloride is the first listed.
NCT01310296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310296 about?
NCT01310296 is a clinical study titled "Lofexidine ADME & Mass Balance in Volunteers". The purpose of this study is to determine the mass balance and absolute bioavailability of a single oral dose of 14C-labeled lofexidine compared to a single intravenous dose of lofexidine.
What is the current status of trial NCT01310296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01310296?
The interventions under investigation include: Lofexidine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01310296?
This trial is sponsored by USWM, LLC (dba US WorldMeds), which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.